DE60035120D1 - Behandlung von krebserkrankungen durch aplidin - Google Patents

Behandlung von krebserkrankungen durch aplidin

Info

Publication number
DE60035120D1
DE60035120D1 DE60035120T DE60035120T DE60035120D1 DE 60035120 D1 DE60035120 D1 DE 60035120D1 DE 60035120 T DE60035120 T DE 60035120T DE 60035120 T DE60035120 T DE 60035120T DE 60035120 D1 DE60035120 D1 DE 60035120D1
Authority
DE
Germany
Prior art keywords
aplidine
treatment
tumor
cancer disorders
complementing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035120T
Other languages
English (en)
Other versions
DE60035120T2 (de
Inventor
Glynn Thomas Faircloth
Chris Twelves
Luis Paz-Ares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of DE60035120D1 publication Critical patent/DE60035120D1/de
Publication of DE60035120T2 publication Critical patent/DE60035120T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE60035120T 1999-11-15 2000-11-15 Behandlung von krebserkrankungen durch aplidin Expired - Lifetime DE60035120T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB9927006 1999-11-15
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0005701 2000-03-09
GB0007639 2000-03-29
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496 2000-06-23
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209 2000-10-13
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (2)

Publication Number Publication Date
DE60035120D1 true DE60035120D1 (de) 2007-07-19
DE60035120T2 DE60035120T2 (de) 2008-01-31

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035120T Expired - Lifetime DE60035120T2 (de) 1999-11-15 2000-11-15 Behandlung von krebserkrankungen durch aplidin

Country Status (27)

Country Link
US (1) US20090298752A1 (de)
EP (1) EP1229922B1 (de)
JP (1) JP2003514025A (de)
KR (1) KR100518986B1 (de)
CN (1) CN1423564A (de)
AT (1) ATE363910T1 (de)
AU (1) AU780417B2 (de)
BG (1) BG65381B1 (de)
BR (1) BR0015811A (de)
CA (1) CA2391502A1 (de)
CY (1) CY1106825T1 (de)
CZ (1) CZ302498B6 (de)
DE (1) DE60035120T2 (de)
DK (1) DK1229922T3 (de)
ES (1) ES2288486T3 (de)
HK (1) HK1045648B (de)
HU (1) HUP0203906A2 (de)
IL (1) IL149488A0 (de)
MX (1) MXPA02004862A (de)
NO (1) NO330719B1 (de)
NZ (1) NZ518847A (de)
PL (1) PL200922B1 (de)
PT (1) PT1229922E (de)
RU (1) RU2261104C2 (de)
SI (1) SI1229922T1 (de)
SK (1) SK287762B6 (de)
WO (1) WO2001035974A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1479622A (zh) 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
DK1603584T3 (da) * 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
EP2117539B1 (de) * 2006-11-03 2010-09-01 Nerviano Medical Sciences S.r.l. Verfahren zur verabreichung einer antitumoralen verbindung
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
KR20100131474A (ko) * 2008-03-07 2010-12-15 파르마 마르 에스.에이. 개선된 항암치료
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
EP0220453B1 (de) * 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
CA2180260A1 (en) * 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2405779A1 (en) * 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7175849B2 (en) * 2000-10-05 2007-02-13 Immunex Corporation Nectin polypeptides
CN1479622A (zh) * 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
DK1603584T3 (da) * 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
WO2004084812A2 (en) * 2003-03-21 2004-10-07 Joullie Madeleine M Tamandarin analogs and fragments thereof and methods of making and using
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments

Also Published As

Publication number Publication date
ATE363910T1 (de) 2007-06-15
CZ20021697A3 (cs) 2003-02-12
NO20022293D0 (no) 2002-05-14
DE60035120T2 (de) 2008-01-31
CY1106825T1 (el) 2012-05-23
SK287762B6 (sk) 2011-09-05
US20090298752A1 (en) 2009-12-03
NO330719B1 (no) 2011-06-20
BG65381B1 (bg) 2008-05-30
PT1229922E (pt) 2007-09-12
MXPA02004862A (es) 2003-01-28
SI1229922T1 (sl) 2008-04-30
NZ518847A (en) 2004-02-27
CZ302498B6 (cs) 2011-06-15
HK1045648A1 (en) 2002-12-06
HUP0203906A2 (en) 2003-03-28
IL149488A0 (en) 2002-11-10
JP2003514025A (ja) 2003-04-15
PL355335A1 (en) 2004-04-19
KR20020064313A (ko) 2002-08-07
EP1229922A2 (de) 2002-08-14
KR100518986B1 (ko) 2005-10-06
AU1402301A (en) 2001-05-30
EP1229922B1 (de) 2007-06-06
DK1229922T3 (da) 2007-10-08
HK1045648B (zh) 2007-09-21
AU780417B2 (en) 2005-03-17
SK6592002A3 (en) 2003-08-05
RU2002115864A (ru) 2004-01-20
RU2261104C2 (ru) 2005-09-27
WO2001035974A2 (en) 2001-05-25
PL200922B1 (pl) 2009-02-27
BG106714A (en) 2003-02-28
CA2391502A1 (en) 2001-05-25
ES2288486T3 (es) 2008-01-16
NO20022293L (no) 2002-07-05
CN1423564A (zh) 2003-06-11
WO2001035974A3 (en) 2001-11-01
BR0015811A (pt) 2002-08-06

Similar Documents

Publication Publication Date Title
DE60035120D1 (de) Behandlung von krebserkrankungen durch aplidin
DE69840006D1 (de) Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von multiplen Myelom
PL354540A1 (en) Drugs for the treatment of malignant tumours
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
YU69903A (sh) Postupak i dozni oblik za lečenje tumora primenom tegafura, uracila, folne kiseline, paklitaksela i karboplatina
WO2002046416A3 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
WO2000063219A8 (en) Platinum complexes for the treatment of cancer
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
EP0773026A3 (de) NK-1 Rezeptor-Antagonisten zur Behandlung von Krebs
MXPA04002407A (es) Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
WO2004004756A8 (fr) UTILISATION D'ANTAGONISTES DE LA PTHrP POUR TRAITER LE CARCINOME A CELLULES RENALES
DE50301954D1 (de) Liposomale formulierungen von phenylalanin-derivaten
GB0111072D0 (en) Disubstituted 7, 9-guaninium halides

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: FAIRCLOTH, GLYNN THOMAS, CAMBRIDGE, MA, US

Inventor name: TWELVES, CHRIS, BEARSDEN, GLASGOW, GB

Inventor name: PAZ-ARES, LUIS, MADRID, ES

8327 Change in the person/name/address of the patent owner

Owner name: PHARMA MAR, S.A., COLMENAR VIEJO, MADRID, ES

8328 Change in the person/name/address of the agent

Representative=s name: SERWE, K., DIPL.-ING., PAT.-ANW., 54290 TRIER

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MOSELPATENT TRIERPATENT, 54290 TRIER

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE SERWE & DR. WAGNER, 54290 TRIER